{
    "Clinical Trial ID": "NCT01419197",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Trastuzumab Emtansine",
        "  Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or unmanageable toxicity.",
        "INTERVENTION 2: ",
        "  Treatment of Physician's Choice",
        "  Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Adult participants  18 years of age.",
        "  Histologically or cytologically documented breast cancer.",
        "  Metastatic or unresectable locally advanced/recurrent breast cancer.",
        "  HER2-positive disease by prospective laboratory confirmation.",
        "  Disease progression on the last regimen received as defined by the investigator.",
        "  Prior treatment with an trastuzumab, a taxane, and lapatinib.",
        "  Disease progression after at least two regimens of HER2-directed therapy in the metastatic or unresectable locally advanced/recurrent setting.",
        "  Adequate organ function, as evidenced by laboratory results.",
        "  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.",
        "  Left ventricular ejection fraction (LVEF)  50% by echocardiogram or multi gated acquisition scan.",
        "Exclusion Criteria:",
        "  Chemotherapy  21 days before first study treatment.",
        "  Trastuzumab  21 days before first study treatment.",
        "  Lapatinib  14 days before first study treatment.",
        "  Prior enrollment in a trastuzumab emtansine containing study, regardless whether the patient received prior trastuzumab emtansine.",
        "  Brain metastases that are untreated or symptomatic, or require any radiation, surgery or corticosteroid therapy to control symptoms within 1 month of randomization."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression-free Survival",
        "  Progression-free survival was defined as the time from randomization to the first documented disease progression by investigator assessment using Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 or death from any cause, whichever occurred first. Progression-free survival was a co-primary endpoint.",
        "  Time frame: Baseline to the clinical cut-off date of 11 Feb 2013 (up to 2 years)",
        "Results 1: ",
        "  Arm/Group Title: Trastuzumab Emtansine",
        "  Arm/Group Description: Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or unmanageable toxicity.",
        "  Overall Number of Participants Analyzed: 404",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  6.2        (5.59 to 6.87)",
        "Results 2: ",
        "  Arm/Group Title: Treatment of Physician's Choice",
        "  Arm/Group Description: Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.",
        "  Overall Number of Participants Analyzed: 198",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  3.3        (2.89 to 4.14)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 102/403 (25.31%)",
        "  Anaemia 1/403 (0.25%)",
        "  Febrile neutropenia 1/403 (0.25%)",
        "  Granulocytopenia 0/403 (0.00%)",
        "  Neutropenia 1/403 (0.25%)",
        "  Thrombocytopenia 1/403 (0.25%)",
        "  Cardiac failure 1/403 (0.25%)",
        "  Vertigo 1/403 (0.25%)",
        "  Hypercalcaemia of malignancy 0/403 (0.00%)",
        "  Vision blurred 1/403 (0.25%)",
        "  Abdominal discomfort 0/403 (0.00%)",
        "  Abdominal pain 4/403 (0.99%)",
        "Adverse Events 2:",
        "  Total: 41/184 (22.28%)",
        "  Anaemia 2/184 (1.09%)",
        "  Febrile neutropenia 7/184 (3.80%)",
        "  Granulocytopenia 1/184 (0.54%)",
        "  Neutropenia 2/184 (1.09%)",
        "  Thrombocytopenia 1/184 (0.54%)",
        "  Cardiac failure 0/184 (0.00%)",
        "  Vertigo 0/184 (0.00%)",
        "  Hypercalcaemia of malignancy 1/184 (0.54%)",
        "  Vision blurred 0/184 (0.00%)",
        "  Abdominal discomfort 1/184 (0.54%)",
        "  Abdominal pain 3/184 (1.63%)"
    ]
}